My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Neuraptive Therapeutics, Inc.

Neuraptive Therapeutics, Inc. Announces First Patient Enrolled in Phase 3 Clinical Trial Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment of Upper Extremity Transected Nerves Requiring Surgical Repair
From Neuraptive Therapeutics, Inc.
Via Business Wire
Neuraptive Therapeutics Receives FDA Breakthrough Therapy Designation for NTX-001 and Provides Update on the Advancements of NTX-001 for the Treatment of Peripheral Nerve Injury Requiring Repair
From Neuraptive Therapeutics, Inc.
Via Business Wire
Neuraptive Therapeutics, Inc. Announces Positive 24-Week Data for NTX-001 in the Phase 2 NEUROFUSE Study, Reinforcing Previously Announced Proof of Concept 12-Week Data
From Neuraptive Therapeutics, Inc.
Via Business Wire
Neuraptive Therapeutics, Inc. Announces Achievement of Proof of Concept in The NEUROFUSE Study of NTX-001 for the Adjunct Treatment of Transected Peripheral Nerves
From Neuraptive Therapeutics, Inc.
Via Business Wire
Neuraptive Therapeutics, Inc. Strengthens its Board of Directors With Appointment of Cary Sucoff, J.D.
From Neuraptive Therapeutics, Inc.
Via Business Wire
Neuraptive Therapeutics, Inc. Announces Appointment of Leading Industry Executive, Dr. Robert R. Ruffolo as New Director to the Board
From Neuraptive Therapeutics, Inc.
Via Business Wire
Neuraptive Therapeutics Announces Key Organizational Updates to Support the Company’s Advancements in Nerve Repair
From Neuraptive Therapeutics, Inc.
Via Business Wire
Neuraptive Therapeutics Announces First Patient Enrolled in a Phase 2 Trial of NTX-001 for the Prevention of Facial Paralysis and Provides Update on the Phase 2 Study of NTX-001 in Peripheral Nerve Injuries due to Trauma
From Neuraptive Therapeutics, Inc.
Via Business Wire
Neuraptive Therapeutics Announces FDA Clearance of a Second IND Application for NTX-001 in the Prevention of Postoperative Facial Paralysis and Plans to Initiate a Phase 2 Clinical Study Later This Year
From Neuraptive Therapeutics, Inc.
Via Business Wire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.